South Korea’s two leading biopharmaceutical companies, Samsung Biologics and Celltrion, unveiled ambitious plans to enter the ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

We recently published a list of 5 Stocks That Analysts Are Bearish On. In this article, we are going to take a look at where ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Kevin Sayer said at the J.P. Morgan Healthcare Conference that Dexcom also expects to release a 15-day glucose sensor in the second half of the year.

The fixed-income trading business posted $2.74 billion in revenue, driven by gains in currencies, mortgages and credit ...

JPMorgan Chase & Co. has released its fourth-quarter and full-year 2024 financial results. Results can be found at the Firm’s ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Alignment Healthcare is looking a bit lonely at the J.P. Morgan Healthcare Conference. CEO John Kao doesn’t really mind.